𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Coregulatory effects of epidermal growth factor, dihydrotestosterone, and prolactin on benign human prostatic hyperplasia tissue culture proliferation

✍ Scribed by Janssen, Thierry; Petein, Michel; van Velthoven, Roland; De Decker, Robert; Assenmacher, Christophe; Corbusier, André; Pasteels, Jean-Lambert; Kiss, Robert; Schulman, Claude


Publisher
John Wiley and Sons
Year
1997
Tongue
English
Weight
321 KB
Volume
30
Category
Article
ISSN
0270-4137

No coin nor oath required. For personal study only.

✦ Synopsis


BACKGROUND.

A variety of hormones have demonstrated effects on prostatic tissue growth dynamics. Our goal was to define the effect of dihydrotestosterone (DHT), epidermal growth factor (EGF), and prolactin (PRL) on prostate cellular proliferation. METHODS. Thirty benign human prostatic hyperplasias (BPH) were maintained 48 hr as in vitro cultures. Culture media were supplemented with EGF, DHT, and PRL alone and in combinations. Proliferation was assessed by labeling with tritiated thymidine. RESULTS. The proliferative response of individual BPH cultures was heterogeneous. DHT and EGF tended to have a greater proliferative effect than PRL, both in terms of the percent cultures responding and the magnitude of the response. PRL antagonized EGF-induced proliferative effects. EGF-and PRL-mediated effects correlated with each other, while DHTmediated effects did not correlate with either those of PRL or EGF. CONCLUSIONS: The proliferative response of individual BPH to DHT, EGF, and PRL, alone or in combination, is too variable to define a predictable response to their influence. Our methodology represents a technique with the capacity to define therapeutic potential for individual cases.


📜 SIMILAR VOLUMES


Effects of long-term treatment withSeren
✍ Di Silverio, F.; Monti, S.; Sciarra, A.; Varasano, P.A.; Martini, C.; Lanzara, S 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 English ⚖ 191 KB 👁 1 views

## Background: The n-hexane lipido-sterol extract of serenoa repens (lsesr, permixon, pierre fabre medicament, castres, france), a phytotherapeutic agent used in the treatment of benign prostatic hyperplasia (bph), has a multisite mechanism of action including inhibition of types 1 and 2 5alpha-red